Antithrombotic properties of hemofilter coated with polymer having a hydrophilic blood-contacting layer

Masashi Tagaya¹, Kazunobu Hara¹, Shunsuke Takahashi², Saki Nagoshi³, Hiroki Handa¹, Shinya Okano¹ and Takuo Murataka¹

Abstract
Objective: Extracorporeal circulation devices are coated with a biocompatible polymer coating agent (BPCA) that has a hydrophilic blood-contacting layer, but hemofilters are not. We aimed to investigate the antithrombotic properties of a BPCA-coated hemofilter.

Methods: Four experiments using BPCA-coated circuits and non-coated hemofilters and four experiments using BPCA-coated circuits and BPCA-coated hemofilters were performed with whole human blood and compared by measuring the circuit pressure every 5 min, antithrombin activity every 40 min, and thrombin–antithrombin complex every 40 min, for a total of 240 min of recirculation.

Results: The mean time required for the pressure at the inlet of the hemofilter to increase sharply was longer in BPCA-coated than in non-coated hemofilters (66 ± 11 min vs 25 ± 9 min, p < 0.01). The mean antithrombin activity value at 200 and 240 min of recirculation was significantly higher in the experiments with BPCA-coated versus non-coated hemofilters (43.3 ± 2.87 vs 33.3 ± 5.74, p = 0.04; 42.8 ± 3.59 vs 31.0 ± 5.35, p = 0.01, respectively); the antithrombin activity values at the other time points were not significantly different. Furthermore, all thrombin–antithrombin complex values in experiments with the BPCA-coated hemofilters achieved overrange at 80 min of recirculation, whereas those with the non-coated hemofilter achieved overrange at 40 min.

Conclusion: This study suggests that BPCA-coated hemofilters can inhibit antithrombin consumption, contributing to antithrombotic effects in extracorporeal circulation circuits.

Keywords
Antithrombin, cardiopulmonary bypass, dialysis, hemofilter, polymer, thrombin–antithrombin complex

Introduction
Currently, in the field of cardiopulmonary bypass surgery, the foreign surfaces of extracorporeal circulation circuit devices, such as polyvinyl chloride tubes, hard-shell reservoirs, and oxygen membranes, are coated with a biocompatible polymer coating agent (BPCA) to reduce thrombogenicity.¹–³ BPCA is composed of a hydrophobic backbone that adheres to circuit surfaces and a hydrophilic blood-contacting layer. The hydrophilic layer swells upon contact with blood, creating a water-filled boundary layer that maintains protein conformation and prevents surface activation.⁴ Without this coating, the blood is exposed to the circuit surface, activating the coagulation cascade.

Although most devices in the cardiopulmonary bypass circuit are coated with BPCA, the hemofilter, which is used...
Tagaya et al.

89

for blood concentration or blood filtration, is not coated with BPCA.

Hemofilters are made of more than 10,000 hollow fibers consisting of a polymer membrane. The polymer membrane has side pores through which molecules can pass. The pore size is important for proper filtration performance; only molecules smaller than the pore can pass, maintaining the concentrations of molecules larger than the pore. For example, one type of hemofilter, the high-flux membrane, is widely used in hemofiltration; this filter has $<0.01$ and $\geq 0.6$ sieving coefficients for albumin and beta-2-microglobulin, respectively. Thus, albumin can only minimally pass, but beta-2-microglobulin can more readily pass through the membrane pores. Considering the principle of filtration, BPCA coating might be unsuitable in hemofilters because of the potential for the coating agent to expand on the membrane surface, narrowing the pore diameter.

If a BPCA-coated hemofilter could be used, favorable effects could be expected in terms of anticoagulation of the extracorporeal circulation, not only in cardiopulmonary bypass surgeries but also in hemodialysis treatment. In a patient undergoing hemodialysis, the blood is exposed to the hemofilter three times a week for 4–5 h per session; therefore, antithrombotic properties are required.

To clarify the features of BPCA-coated hemofilters, we previously performed experiments to confirm that the BPCA coating did not disturb functions of diffusion and filtration and found that there is no malfunction of filtration and diffusion in BPCA-coated hemofilters. Therefore, further investigation of BPCA-coated hemofilters to evaluate the antithrombotic effects is justified.

In this study, we aim to examine the anticoagulation effects of BPCA-coated hemofilters in contact with whole human blood using in vitro experiments.

**Methods**

In vitro experiments were performed to compare circuit pressures and blood coagulation markers in blood exposed to BPCA-coated and non-coated hemofilters at similar exposure durations.

**Materials**

The BPCA product (SEC-1™; Toyobo, Osaka, Japan) used in this study was a copolymer composed of hydrophobic alkyl acrylate, hydrophilic polyethylene glycol acrylate, and water-repellent silicone methacrylate. The coating procedure involved spreading the BPCA layer using a solvent. Eight columns consisting of polyethersulfone membrane (Hemocrystal; MERA, Tokyo, Japan), which had the same lot number, were employed as hemofilters in this study. Hemocrystals had 1.1 m² membranes and are considered high-flux membranes; the sieving coefficients of beta-2-microglobulin and albumin were 0.6 and $\leq 0.01$, respectively.

An experimental circuit was configured consisting of a soft bag reservoir, polyvinyl chloride tubes, chambers, and a hemofilter and was installed with a roller pump, an infusion pump, and two digital manometers, which can measure pressure up to 500 mmHg (Figure 1). Four experimental circuits coated with BPCA on the foreign surfaces of the circuit configurations including the hemofilter (PC1,2,3,4)

---

**Figure 1.** Experimental circuit. Human blood was collected in a soft bag reservoir, vibrated on the vibrator, and circulated with a roller pump. Two chambers were configured at the inlet and outlet pathways of the hemofilter to measure each pathway’s pressure. A line for protamine administration was positioned at the pathway before the inlet chamber, and protamine was administered by infusion pump. A sampling port was positioned at the pathway before the roller pump.
were prepared, and four experimental circuits coated with BPCA on the foreign surfaces of the circuit configurations excluding the hemofilter (NC1,2,3,4) were also prepared. Those devices were coated with BPCA using the solvent infiltration method.

To evaluate the anticoagulation effects precisely, whole human blood was used. We recruited healthy volunteers, who each provided 200 mL of whole blood. A healthy volunteer was defined as having a hemoglobin (HGB) concentration $>13.5$ g/dL, with no medical events within the prior 1 month, no transfusion history, and no current disease diagnosis. The ethic committees of the National Hospital Organization Kure Medical Center approved this study protocol, and written informed consent was obtained from each volunteer.

**Procedures**

For blood collection, a soft bag reservoir was prepared and 3000 units of unfractionated heparin were added to the reservoir. The blood was added to the soft bag reservoir using a 17-gauge needle, and the reservoir was continually shaken thoroughly in the vibrator during the test. Upon collecting 200 mL of blood, the soft bag reservoir was disconnected from the needle and was connected to the experimental circuit, which was primed with saline. The hemofilter was filled with primed saline, filling both the inside and the outside of the membrane. The blood was recirculated at 300 mL/min with a roller pump to mix the blood with pre-primed saline in the circuit. After 3 min, 15 mg/min of protamine was administered to the circuit to reverse the heparinization. When 50 mg of total protamine was administered, administration was stopped. After 3 min, 6 mL of blood was sampled at the sampling port to evaluate baseline coagulation markers. Subsequently, the blood recirculation rate was changed from 300 to 100 mL/min, and the blood was continually recirculated for 240 min. The pressures at the inlet and outlet chambers were measured every 5 min. An amount of 6 mL of blood was sampled every 40 min to measure coagulation markers.

To compare BPCA-coated versus non-coated hemofilters, similar experiments were performed with four circuits using a BPCA-coated hemofilter and four circuits using a non-coated hemofilter. All experiments were performed in a room maintained at a temperature of 38°C.

The sampled blood was used to measure HGB, prothrombin time of international normalized ratio (PT-INR), antithrombin activity (ATA), and thrombin–antithrombin complex (TAT). HGB was measured using a hematology analyzer (KX-21; Sysmex, Hyogo, Japan). For PT-INR, the transmitted light detection method (HemosIL RecombiPlas Tin; Instrumentation Laboratory Company, Bedford, MA, USA) was used. For ATA, the synthetic substrate method (HemosIL Antithrombin; Instrumentation Laboratory Company) was used. For TAT, the chemiluminescent enzyme immunoassay (STACIA CLEIA TAT; LSI Medience Corp., Tokyo, Japan) was used; the upper limit of detection for this assay was 120 ng/mL.

**Statistical analysis**

Continuous variables were compared using Student's t-test performed using MS Excel software (Microsoft Corp., Redmond, WA, USA). The significance level was set at $\alpha = 0.05$.

**Results**

The measured pressures at the inlet chambers in BPCA-coated and non-coated hemofilters were plotted and joined, as shown in Figure 2. The mean time ($n=4$) when the pressure rose sharply, defined as the point when pressure increased $>50$ mmHg in 5 min, was longer in BPCA-coated than in non-coated hemofilters ($66 \pm 11$ min vs $25 \pm 9$ min, $p<0.01$). All measured pressure values at the outlet chambers in each experiment were $<60$ mmHg.

Table 1 reports the coagulation markers measured every 40 min in each experiment. The ATA and TAT values according to recirculated duration are shown in Figures 3 and 4, respectively. The ATA mean value ($n=4$) at 200 and 240 min of recirculation was significantly higher in the experiments with BPCA-coated compared with non-coated hemofilters ($43.3 \pm 2.87$ vs $33.3 \pm 5.74$, $p=0.04$; $42.8 \pm 3.59$ vs $31.0 \pm 5.35$, $p=0.01$), whereas
the values at other time points were not significantly different. The TAT values in experiments with the BPCA-coated hemofilters were over the limit of detection at 80 min of recirculation; with the non-coated hemofilters, TAT values were over the limit of detection at 40 min.

**Discussion**

Many reports have been published regarding the biocompatibility of BPCA-coated medical equipment.¹¹–¹³ The results of this study confirm the beneficial effect, in terms of anticoagulation, of the BPCA-coated hemofilter.

The pressure measurements suggest that the time required before the initiation of coagulation is significantly later in the circuits with BPCA-coated hemofilters compared with non-coated hemofilters. Because surfaces that contacted blood in each experimental circuit were all coated with BPCA, with the exception of the hemofilter, the only difference in the two experimental groups was the presence of the hemofilter in each circuit.

### Table 1. Measured values in each circulated duration.

| Experiment | Measurement | Circulated duration (min) |
|------------|-------------|--------------------------|
|            |             | 0 | 40 | 80 | 120 | 160 | 200 | 240 |
| PC₁        | HGB (g/dL)  | 9.8 | 9.9 | 10.1 | 10.2 | 10.3 | 10 | 9.9 |
|            | PT-INR      | 1.94 | 2.09 | 2.18 | N/A | N/A | N/A | N/A |
|            | ATA (%)     | 52 | 50 | 49 | 45 | 41 | 43 | 41 |
|            | TAT (ng/mL) | 1.2 | 14.4 | >120 | >120 | >120 | >120 | >120 |
| PC₂        | HGB         | 8.6 | 9.3 | 8.7 | 8.7 | 8.7 | 8.7 | 8.7 |
|            | PT-INR      | 1.83 | 1.78 | N/A | N/A | N/A | N/A | N/A |
|            | ATA         | 55 | 56 | 47 | 45 | 46 | 47 | 48 |
|            | TAT         | 1.4 | 24.8 | >120 | >120 | >120 | >120 | >120 |
| PC₃        | HGB         | 7.8 | 8.3 | 7.3 | 7.4 | 7.5 | 7.5 | 7.6 |
|            | PT-INR      | 2.11 | 2.03 | N/A | N/A | N/A | N/A | N/A |
|            | ATA         | 50 | 54 | 44 | 40 | 39 | 40 | 40 |
|            | TAT         | <1.0 | 8.1 | >120 | >120 | >120 | >120 | >120 |
| PC₄        | HGB         | 8.2 | 8.4 | 7.7 | 7.8 | 7.9 | 7.9 | 7.8 |
|            | PT-INR      | 2.24 | 2.44 | N/A | N/A | N/A | N/A | N/A |
|            | ATA         | 50 | 47 | 38 | 35 | 37 | 37 | 37 |
|            | TAT         | <1.0 | 9.2 | >120 | >120 | >120 | >120 | >120 |
| NC₁        | HGB         | 8.4 | 8.3 | 8.3 | 8.3 | 8.3 | 8.2 | 8.2 | 8.3 |
|            | PT-INR      | 2.15 | N/A | N/A | N/A | N/A | N/A | N/A |
|            | ATA         | 42 | 38 | 37 | 33 | 33 | 34 | 34 |
|            | TAT         | 1.1 | >120 | >120 | >120 | >120 | >120 | >120 |
| NC₂        | HGB         | 9.4 | 8.6 | 8.6 | 8.6 | 8.5 | 8.6 | 8.6 |
|            | PT-INR      | 1.99 | N/A | N/A | N/A | N/A | N/A | N/A |
|            | ATA         | 47 | 33 | 26 | 25 | 23 | 25 | 23 |
|            | TAT         | 82.5 | >120 | >120 | >120 | >120 | >120 | >120 |
| NC₃        | HGB         | 8.3 | 8.5 | 8.3 | 8.2 | 8.2 | 8.2 | 8.2 |
|            | PT-INR      | 1.85 | N/A | N/A | N/A | N/A | N/A | N/A |
|            | ATA         | 52 | 50 | 41 | 35 | 37 | 36 | 34 |
|            | TAT         | 1.5 | >120 | >120 | >120 | >120 | >120 | >120 |
| NC₄        | HGB         | 7.2 | 6.9 | 7.3 | 7.2 | 7.2 | 7.1 | 7.1 |
|            | PT-INR      | 2.30 | N/A | N/A | N/A | N/A | N/A | N/A |
|            | ATA         | 42 | 41 | 38 | 39 | 36 | 38 | 33 |

PCₙ: number of experiments with polymer-coated hemofilter; NCₙ: number of experiments with non-coated hemofilter; HGB: hemoglobin; PT-INR: prothrombin time of international normalized ratio; ATA: antithrombin activity; TAT: thrombin–antithrombin complex; N/A: not applicable.

![Figure 3](image-url) Measured values of antithrombin activity (ATA) every 40 min of blood recirculation. Red dotted lines indicate ATA transition every 40 min of recirculation in the experiments with biocompatible polymer–coated hemofilters; black solid lines indicate those with non-coated hemofilters. The horizontal axis indicates recirculated duration, and the vertical axis indicates ATA (%).
Considering the cardiopulmonary bypass circuit, the BPCA-coated hemofilter is valuable. Because a hemofilter is mainly used for concentration of blood, due to its filtration functions, blood circulates into a hemofilter over a prolonged duration during extracorporeal circulation. Furthermore, a hemofilter is used for various perfusion techniques such as modified ultrafiltration, dilutional ultrafiltration, zero-balance ultrafiltration, or any other hemopurification method. These techniques also require blood circulation into a hemofilter for prolonged duration. Considering that the BPCA-coated hemofilter reduces antithrombin consumption, it could produce beneficial effects during the post-extracorporeal circulation phase. Postoperative ATA has been reported to be associated with major adverse cardiac events, regardless of preoperative ATA. Furthermore, post-extracorporeal circulation ATA inversely correlates with the need for transfusion or the development of acute renal failure. Therefore, the BPCA-coated hemofilter, which can preserve ATA, could lead to reduced mortality in cardiopulmonary bypass surgeries. Furthermore, there are many reports concerning the favorable effects of BPCAs on the reduction of cell adhesion, hemolysis, protein adhesion, and inflammatory markers. Another advantage of the BPCA-coated hemofilter is its biocompatibility, which could help improve the prognosis of patients undergoing extracorporeal circulation.

Regarding hemodialysis, the BPCA-coated hemofilter is also valuable, in particular, for successful treatment of patients with acute kidney injury. Acute kidney injury is a systemic inflammatory condition, and its inflammatory response can trigger the activation of both the intrinsic and extrinsic coagulation cascades, inducing thromboembolism in the extracorporeal circuit regardless of heparinization. Therefore, preservation of antithrombin levels might enhance the longevity of the extracorporeal circuit in patients requiring continuous renal replacement therapy. Furthermore, as many centers practice anticoagulant-free hemodialysis with the BPCA-coated filter and bovine blood. In this study, experiments were performed; therefore, future studies with a
higher number of experiments are required to confirm our findings.

Conclusion
The results of this study show that the BPCA-coated hemofilter can delay circuit thrombogenicity and inhibit antithrombin consumption compared with the non-coated hemofilter. This preliminary study suggests that a BPCA-coated hemofilter is superior in terms of antithrombotic properties.

Acknowledgements
The authors are grateful for the valuable advice provided by Hironori Izutani, Professor of the Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Ehime, Japan; Masahide Yakehiro, Professor of the Department of Physiology, Hiroshima International University, Hiroshima, Japan; Morhiro Matsuda, Director of the Department of General Medicine, Kawasaki Hospital, Kobe, Japan; Andrew Dinale and Adam Roshan, Perfusionists at the Department of Cardiothoracic Surgery, St Vincent’s Hospital, New South Wales, Australia; and Kiyoshi Yoshida, associate professor of the Department of Advanced Clinical Engineering at Osaka University Graduate School of Medicine, Osaka, Japan. The authors are also grateful for the analytical assistance provided by Eiji Morimoto, LSI Medience Corp., Hiroshima, Japan.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was conducted with a grant from the Policy-Based Medical Services Foundation, Japan.

References
1. Ranucci M, Pazzaglia A, Isgrò G, et al. Closed, phosphorylcholine-coated circuit and reduction of systemic heparinization for cardiopulmonary bypass: the intraoperative ECMO concept. Int J Artif Organs 2002; 25(9): 875–881.
2. Yoshizaki T, Tabuchi N, Van Oeveren W, et al. PMEA polymer-coated PVC tubing maintains antithrombogenic properties during in vitro whole blood circulation. Int J Artif Organs 2005; 28: 834–840.
3. Fukui T, Nishida H and Takanashi S. Biocompatibility of cardiopulmonary bypass circuit with new polymer Senko E-Ternal Coating™. Perfusion 2015; 30(7): 572–579.
4. Ask A, Holt D and Smith L. In vivo comparison study of FDA-approved surface-modifying additives and poly-2-methoxyethylacrylate circuit surfaces coatings during cardiopulmonary bypass. J Extra Corpor Technol 2006; 38(1): 27–32.
5. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005; 16(8): 2421–2430.
6. Buoncristiani U. Fifteen years of clinical experience with daily haemodialysis. Nephrol Dial Transplant 1998; 13(Suppl. 6): 148–151.
7. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347(25): 2010–2019.
8. Tagaya M, Takahashi S, Matsuda M, et al. Prospects for clinical applications of polymer-coated haemoconcentrator on extracorporeal circuit in cardiopulmonary bypass surgeries. Int J Artif Organs 2016; 39(8): 415–420.
9. Tagaya M, Nagoshi S, Matsuda M, et al. Hemodialysis membrane coated with a polymer having a hydrophilic blood–contacting layer can enhance diffusion performance. Int J Artif Organs 2017; 40(12): 665–669.
10. Pharmaceuticals Medical Devices Agency. Product information (in Japanese), http://www.info.pmda.go.jp/downfiles/md/PDF/530360/530360_21400BZZ00061A02_A_01_02.pdf (accessed 16 May 2018).
11. Sohn N, Marcoux J, Mycck T, et al. The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress. Perfusion 2009; 24(4): 231–237.
12. Suzuki Y, Daitoku K, Minakawa M, et al. Poly-2-methoxyethylacrylate-coated bypass circuits reduce activation of coagulation system and inflammatory response in congenital cardiac surgery. J Artif Organs 2008; 11(3): 111–116.
13. Iwasaki Y, Sawada S, Ishihara K, et al. Reduction of surface-induced inflammatory reaction on PLGA/MPC polymer blend. Biomaterials 2002; 23(18): 3897–3903.
14. Hoek JA, Sturk A, ten Cate JW, et al. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 1988; 34(10): 2058–2062.
15. Deguchi K, Noguchi M, Yuwasaki E, et al. Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am J Hematol 1991; 38(2): 86–89.
16. Lucchi L, Ligabue G, Marietta M, et al. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit. Artif Organs 2006; 30(2): 106–110.
17. Koyama K, Madoiwa S, Nunomiya S, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care 2014; 18(1): R13.
18. Roemisch J, Gray E, Hoffmann JN, et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2003; 13(8): 657–670.
19. Hayakawa M. Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments. Open Access Emerg Med 2017; 10: 25–29.
20. Osipov VP, Lurie GO, Khodas Mikhailov Yu, et al. Hemoconcentration during open heart operations. Thorac Cardiovasc Surg 1985; 33(2): 81–85.
21. Harm SK, Waters JH, Lynn P, et al. Changes in mechanical fragility and free hemoglobin levels after processing salvaged cardiopulmonary bypass circuit blood with a modified ultrafiltration device. J Extra Corpor Technol 2012; 44(1): 21–25.
22. Iino K, Tomita S, Yamaguchi S, et al. Successful aortic valve replacement using dilutional ultrafiltration during
cardiopulmonary bypass in a patient with Child-Pugh class C cirrhosis. *Interact Cardiovasc Thorac Surg* 2008; 7(2): 331–332.

23. Heath M, Raghunathan K, Welsby I, et al. Using zero balance ultrafiltration with dialysate as a replacement fluid for hyperkalemia during cardiopulmonary bypass. *J Extra Corpor Technol* 2014; 46(3): 262–266.

24. Tagaya M, Matsuda M, Yakehiro M, et al. Prospect for using a hemoconcentrator as an alternative hemodialysis method in cardiopulmonary bypass surgeries. *Perfusion* 2014; 29: 117–123.

25. Tagaya M, Matsuda M, Yakehiro M, et al. Features of an alternative hemodialysis method using a hemoconcentrator during cardiopulmonary bypass surgeries. *Perfusion* 2015; 30(4): 318–322.

26. Garvin S, Muchlschlegel JD, Perry TE, et al. Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgery. *Anesth Analg* 2010; 111: 862–869.

27. Muñoz V, Barettino D, D’Ocon P, et al. Antithrombin activity and outcomes in patients undergoing cardiac surgery with cardiopulmonary bypass. *Blood Coagul Fibrinolysis* 2013; 24(4): 454–457.

28. Kocakulak M, Ozgürtaş T and Ayhan H. Effect of poly (2-methoxyethyl acrylate)-coated oxygenators on haemolysis. *J Biomater Sci Polym Ed* 2006; 17(4): 449–460.

29. Zheng Z, Ren L, Zhai Z, et al. Surface modification on polyethylene terephthalate films with 2-methacryloyloxyethyl phosphorylcholine. *Mater Sci Eng C Mater Biol Appl* 2013; 33(5): 3041–3046.

30. Ratliff BB, Rabadi MM, Vasko R, et al. Messengers without borders: mediators of systemic inflammatory response in AKI. *J Am Soc Nephrol* 2013; 24(4): 529–536.

31. Al-Dorzi HM, Al-Heijan A, Tamim HM, et al. Renal failure as a risk factor for venous thromboembolism in critically ill patients: a cohort study. *Thromb Res* 2013; 132(6): 671–675.

32. Davenport A. Pre-dilution or post-dilution fluid replacement for continuous veno-venous hemofiltration: that is the question. *Nephron Clin Pract* 2003; 94(4): c83–14.

33. duCheyron D, Bouchet B, Bruel C, et al. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study. *Crit Care* 2006; 10(2): R45.

34. Lavaud S, Paris B, Maheut H, et al. Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. *ASAIO J* 2005; 51(4): 348–351.

35. Richtrova P, Opatrný K Jr, Vít L, et al. The AN69 ST haemodialysis membrane under conditions of two different extracorporeal circuit rinse protocols a comparison of thrombogenicity parameters. *Nephrol Dial Transplant* 2007; 22(10): 2978–2984.

36. Sagedal S, Witzczak BJ, Osnes K, et al. A heparin-coated dialysis filter (AN69 ST) does not reduce clotting during hemodialysis when compared to a conventional polysulfone filter (F×8). *Blood Purif* 2011; 32: 151–155.

37. Schetz M, Van Cromphaut S, Dubois J, et al. Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation? *Intensive Care Med* 2012; 38(11): 1818–1825.

38. Iwasaki Y, Nakabayashi N and Ishihara K. In vitro and ex vivo blood compatibility study of 2-methacryloyloxyethyl phosphorylcholine (MPC) copolymer-coated hemodialysis hollow fibers. *J Artif Organs* 2003; 6(4): 260–266.